KIWA Biotech - OTCBB mit hohem Potential - 500 Beiträge pro Seite

[coccinelleberlin]

Hallo,

Ich möchte euch den Wert Kiwa Biotech vorstellen - ein Biotech Unternehmen, dass hauptsächlich in China operiert.
Spezilisiert und Fokussiert auf ein Patent Düngemittel was den Ertrag einer Ernte erheblich steigern kann.

Zu den Zahlen:

Umsatz: 600000$ + 157% YTD Wachstum Annulisiert: ca.2Mill$
Gross Profit: 400000$ 150% Wachstum

Nur noch 27000$ Verlust im vergleichbaren Vorjahresquartla waren es 750000$.
Hier dürfte es bald schwarze Zahlen geben:

Marktkapitalisierung: 1,1 Millionen US $ (Unterbewertet!!)

Tickersymbol in den USA: KWBT (für Yahoo Finance etc.)

[coccinelleberlin]

Hier nochmal der 10Q:


Results of Operations for Three Months and Six Months Ended June 30, 2005 and 2004

NET SALES. Net sales for the three months ended June 30, 2005 were $607,611, an increase of $367,852 or 153%, from $239,759 for the three months ended June 30, 2004. The increase in net sales during the period resulted from the increased number of local and foreign customers in Southeast Asia.

Net sales for the six months ended June 30, 2005 were $1,018,303, an increase of $725,086 or 247%, from $293,217 for the six months ended June 30, 2004. The increase in net sales during the period resulted from the increased number of local and foreign customers in Southeast Asia.

-20-

COST OF SALES. Costs of sales were $205,945 and $76,290 for the three months ended June 30, 2005 and 2004, respectively. The increase of $129,655, or 170%, in cost of sales was primarily due to increased material costs, which resulted from increased sales.

Costs of sales were $280,918 and $107,301 for the six months ended June 30, 2005 and 2004, respectively. The increase of $173,617 or 162%, in cost of sales was primarily due to increased material costs, which resulted from increased sales.

GROSS PROFIT. Gross profit was $401,666 and $163,469, representing a profit margin of 66% and 68% for the three months ended June 30, 2005 and 2004, respectively. This represents a 146% increase in gross profit of $238,197.

Gross profit was $737,385 and $185,916, representing a profit margin of 72% and 63% for the six months ended June 30, 2005 and 2004, respectively. This represents a three-fold increase in gross profit of $551,469.

CONSULTING AND PROFESSIONAL FEES. Consulting and professional fees were $209,824 and $69,573 for the three months ended June 30, 2005 and 2004, respectively, representing an increase of $140,251 or 202%. Consulting and professional fees were $346,397 and $99,460 for the six months ended June 30, 2005 and 2004, respectively, representing an increase of $246,937 or 248%. The increase in consulting and professional fees in both periods is primarily attributable to consulting and professional fees paid on behalf of Cornell Capital for finance and investor relations services. Fees to accountants, lawyers and other fees associated with operating a public company also contributed to the increase in consulting and professional fees in the first half of 2005.

OFFICERS` COMPENSATION. Officers` compensation increased by $5,033 or 43% to $16,632 for the three months ended June 30, 2005 as compared to $11,599 for the three months ended June 30, 2004. The increase is primarily because of the salary adjustment of certain officers and a performance bonus to an officer in 2005.

Officers` compensation increased by $4,684 or 23% to $24,982 for the six months ended June 30, 2005 as compared to $20,298 for the six months ended June 30, 2004. The increase is primarily because of the salary adjustment of certain officers and a performance bonus to an officer in 2005.

GENERAL AND ADMINISTRATIVE. General and administrative expense was $114,334 for the three months ended June 30, 2005, as compared to $201,444 for the same period of 2004, a decrease of $87,110 or 43%, primarily as a result of the decrease of entertainment expenses and insurance expenses during the second quarter of 2005.

General and administrative expense was $362,134 for the six months ended June 30, 2005, as compared to $275,988 for the same period of 2004, an increase of $86,146 or 31%, primarily as a result of increased marketing expenses commensurate with enhanced sales volume and increased personnel-related costs in China reflecting an increased level of business activity and increased costs associated with being a public company.

General and administrative expenses mainly include salaries, travel and entertainment, rent, office expense, telephone expense and insurance costs.

RESEARCH AND DEVELOPMENT. Research and development expense decreased $13,067, or 92%, to $1,143 for the three months ended June 30, 2005, as compared to $14,210 for the three months ended June 30, 2004. The decrease is due to reduction of field testing fees for new products.

Research and development expense decreased $18,328, or 69%, to $8,423 for the six months ended June 30, 2005, as compared to $26,751 for the six months ended June 30, 2004. The decrease is due to reduction of field testing fees for new products.

-21-

DEPRECIATION AND AMORTIZATION. Depreciation and amortization, excluding depreciation and amortization included in cost of sales, increased $13,297, or 158%, to $21,694 for the three months ended June 30, 2005, as compared to $8,397 for the three months ended June 30, 2004. Depreciation and amortization, excluding depreciation and amortization included in cost of sales, increased $33,654, or 192%, to $51,189 for the six months ended June 30, 2005, as compared to $17,535 for the six months ended June 30, 2004. The increase in both periods is primarily attributable to depreciation expense in respect of the patent we finished acquiring in August 2004.

INTEREST INCOME (EXPENSE). Interest expense decreased $528,906, or 89%, to $66,842 for the three months ended June 30, 2005, as compared to interest expense of $595,748 for the three months ended June 30, 2004. Interest expense decreased $601,405, or 82%, to $134,246 for the six months ended June 30, 2005, as compared to interest expense of $735,651 for the six months ended June 30, 2004. This decrease in both periods is due to the termination of the conversion feature of a convertible note that was converted to common stock on June 8, 2004, which the Company had previously amortized as interest expense.

OTHER INCOME. Other income increased $2,416 from nil, for the three months and six months ended June 30, 2005 as compared to the same periods in 2004. The increase arose from a grant from the municipal government in Shandong Province, China, during 2005.

NET INCOME (LOSS). We experienced a net loss of $26,387 for the three months ended June 30, 2005 compared to a net loss of $756,955 for the three months ended June 30, 2004. The decrease of $730,568 or 97% in the current period as compared to second quarter 2004 is primarily due to the decrease of interest expense resulting from the termination of the conversion feature of a convertible note that was converted to common stock on June 8, 2004 and increases in revenue.

Net loss decreased $2,219,631 to $187,570 for the six months ended June 30, 2005 as compared to $2,407,201 for the six months ended June 30, 2004. The decrease in net loss in the current period as compared to the first half of 2004 is primarily due to non-recurring costs of the reverse merger equal to $1,417,434 and the decrease of interest expense resulting from the termination of the conversion feature of a convertible note that was converted to common stock on June 8, 2004.

[coccinelleberlin]

Bereits 15% im Plus.

[coccinelleberlin]

+ 20%

[coccinelleberlin]

BID 0,024
Ask 0,025

[coccinelleberlin]

Schluss auf Tageshoch

+ 25%!

[Margeaux]

die kauft doch keiner bei den Mega-Umsätzen!!!

Margeaux

[coccinelleberlin]

Bereits 2 MM bei 0,024.

nach 0,025 sofort 0,03 im Ask im Level II, schaut gut aus.

[coccinelleberlin]

Volumen zieht an. Ledglich UBS noch im Ask bei 0,025.